RubinS.C., BlackwoodA., BanderaC., BehbakhtK., BenjaminI., RebbeckT.R., BoydJ.: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unse-lected ovarian cancer population: relationship to family history and implications for genetic testing.Am J Obstet Gynecol, 178: 670–677, 1998.
2.
Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge. Fédération Nationale des Centres de Lutte contre le Cancer.Expertise Collective.INSERM, Paris, 1998.
3.
StruewingJ.P., WatsonR., EastonD.F., PonderB.A., LynchH.T., TuckerM.A.: Prophylactic oophorectomy in inherited breast/ovarian cancer families. In: Hereditary Breast Cancer, Ovarian, and Colon Cancer.NCI monographs17: 33–35, 1995.
4.
SchragD., KuntzK.M., GarberJ.E., WeeksJ.C.: Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.N Engl J Med, 336: 1465–1471, 1997.
5.
PiverM.S., JishiM.F., TsukadaY., NavaG.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer.Cancer, 71: 2751–2755, 1993.
6.
NIH concensus development panel on ovarian cancer.Ovarian cancer: screening, treatment, and follow-up.JAMA,273: 491–497, 1995.
7.
BurkeW., DalyM., GarberJ., BotkinJ., Ellis KahnM.J., LynchP., McTiernanA., OffitK., PerlmanJ., PetersenG., ThomsonE., VarricchioC.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2.JAMA, 277: 997–1003, 1997.
8.
MoriceP., PautierP., MercierS., SpatzA., LhomméC., Duvil-lardP., GerbauletA., CastaigneD.: Laparoscopic prophylactic oophorectomies in women with inherited risk of ovarian cancer.Eur J Gynaecol Oncol, 20: 202–204, 1999.
PaleyP.J., SwisherE.M., GarciaR.L., AgoffS.N., GreerB.E., PetersK.L., GoffB.A.: Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.Gynecol Oncol, 80: 176–180, 2001.
11.
RoseP.G., ShrigleyR., WiesnerG.L.: Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report.Gynecol Oncol, 77: 319–320, 2000.
12.
DeligdischL., GilJ., KernerH., WuH.S., BeckD., Gershoni-BaruchR.: Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations.Cancer, 86: 1544–1550, 1999.
13.
SalazarH., GodwinA.K., DalyM.B.: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.JNCI, 88: 1810–1820, 1996.
14.
BarakatR.R., FedericiM.G., SaigoP.E., RobsonM.E., OffitK., BoydJ.: Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.Cancer, 89: 383–390, 2000.
15.
CaseyM.J., BewtraC., HoehneL.L., TatpatiA.D., LynchH.T., WatsonP.: Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.Gynecol Oncol, 78: 278–287, 2000.
16.
StrattonJ.F., BuckleyC.H., LoweD., PonderB.A.: Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation.J Natl Cancer Inst, 91: 626–628, 1999.
17.
RoseP.G., HunterR.E.: Advanced ovarian cancer in a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report.J Repod Med, 39: 908–910, 1994.
18.
LuK.H., GarberJ.E., CramerD.W., WelchW.R., NiloffJ., SchragD., BerkowitzR.S., MutoM.G.: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.J Clin Oncol, 18: 2728–2732, 2000.
19.
MoriceP., PautierP., DalalogeS.: Prophylactic surgery in patients with inherited risk of ovarian cancer (letter).Gynecol Oncol, 2001, in press.
